SOX2 and breast carcinoma: Fourth, we finally evaluated the clinical relevance of iadademstat as a novel anti-SOX2 epigenetic breast cancer therapy by assessing its ability to impact both the expression of SOX2 and the tumorsphere-forming capacity of CSC-like cells derived from breast cancer patient-derived xenografts (PDX).